- Home
- FEBO vs RNAZ Comparison
FEBO vs RNAZ Comparison
Compare FEBO & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FEBO | RNAZ |
|---|---|---|
| Founded | 1993 | 2016 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4M | 8.3M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FEBO | RNAZ |
|---|---|---|
| Price | $0.81 | $8.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.5K | ★ 26.9K |
| Earning Date | 05-12-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $3.82 |
| 52 Week High | $1.46 | $20.99 |
Technical Indicators
Market Signals| Indicator | FEBO | RNAZ |
|---|---|---|
| Relative Strength Index (RSI) | 42.56 | 57.10 |
| Support Level | $0.76 | $6.08 |
| Resistance Level | $1.25 | $9.93 |
| Average True Range (ATR) | 0.06 | 1.22 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 23.42 | 56.05 |
Price Performance
Historical ComparisonAbout FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.